CTLA4 and melanoma: Even while ICIs greatly boosted melanoma patients' chances of survival, 40–65 percent of those taking PD-1 inhibitors and more than 70 percent of those taking CTLA-4 inhibitors did not exhibit positive response, primarily because of the emergence of resistance [50].